Vitamin Shoppe (NYSE:VSI) Upgraded to “Sell” by ValuEngine

ValuEngine upgraded shares of Vitamin Shoppe (NYSE:VSI) from a strong sell rating to a sell rating in a report released on Thursday morning, ValuEngine reports.

A number of other research analysts also recently commented on VSI. Jefferies Financial Group assumed coverage on shares of Vitamin Shoppe in a research note on Monday, June 17th. They set a hold rating and a $4.00 price objective for the company. Zacks Investment Research downgraded shares of Vitamin Shoppe from a buy rating to a hold rating in a research note on Saturday, July 13th. One equities research analyst has rated the stock with a sell rating and four have given a hold rating to the company’s stock. Vitamin Shoppe currently has an average rating of Hold and an average price target of $7.92.

Shares of VSI stock traded up $0.07 during trading on Thursday, reaching $4.38. The company had a trading volume of 212,367 shares, compared to its average volume of 504,907. The stock has a 50 day moving average price of $4.05. The company has a quick ratio of 0.16, a current ratio of 1.14 and a debt-to-equity ratio of 2.36. Vitamin Shoppe has a one year low of $3.32 and a one year high of $13.95. The firm has a market cap of $103.40 million, a P/E ratio of 16.85 and a beta of 1.65.

Vitamin Shoppe (NYSE:VSI) last announced its earnings results on Wednesday, May 8th. The specialty retailer reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.03). Vitamin Shoppe had a net margin of 0.33% and a return on equity of 4.64%. The firm had revenue of $283.33 million during the quarter. As a group, sell-side analysts anticipate that Vitamin Shoppe will post 0.54 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Investors Research Corp bought a new position in Vitamin Shoppe during the first quarter worth $34,000. Optimum Investment Advisors bought a new position in Vitamin Shoppe during the first quarter worth $35,000. Macquarie Group Ltd. lifted its stake in Vitamin Shoppe by 114.0% during the fourth quarter. Macquarie Group Ltd. now owns 10,136 shares of the specialty retailer’s stock worth $48,000 after purchasing an additional 5,400 shares during the last quarter. Great West Life Assurance Co. Can lifted its stake in Vitamin Shoppe by 113.1% during the fourth quarter. Great West Life Assurance Co. Can now owns 20,754 shares of the specialty retailer’s stock worth $90,000 after purchasing an additional 11,014 shares during the last quarter. Finally, Weiss Asset Management LP lifted its stake in Vitamin Shoppe by 56.3% during the first quarter. Weiss Asset Management LP now owns 18,609 shares of the specialty retailer’s stock worth $131,000 after purchasing an additional 6,700 shares during the last quarter. 88.87% of the stock is owned by hedge funds and other institutional investors.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc, through its subsidiaries, operates as a omni-channel specialty retailer and contract manufacturer of nutritional products in the United States and internationally. It operates in two segments, Retail and Manufacturing. The company provides custom manufacturing and private labeling services for vitamin, mineral, and supplement products, as well as develops and markets own branded products.

Read More: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Vitamin Shoppe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe and related companies with MarketBeat.com's FREE daily email newsletter.